

Cover Story
In a 6-6 vote, ODAC says “maybe” to Sutent for adjuvant kidney cancer—
But at FDA “Maybe” has meaningWith frustrating photo finish voting results—6-6—still on the screen, FDA's cancer czar Richard Pazdur delivered an acerbic thank-you to members of the agency's Oncologic Drugs Advisory Committee:“Well, that's the end vote, it makes our job definitely easier,” said Pazdur, director of the FDA's Oncology Center of Excellence, who gets sarcastic sometimes.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Drugs & Targets
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - The White House “skinny budget” document cuts NIH by nearly 40%
The cuts are consistent with the previously leaked “passback” document - NIH cuts threaten U.S. edge in biomedical research: “We are giving China the opportunity of a lifetime”
Cancer research also took center stage at Senate appropriations hearing - TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- AACI letter to NIH’s Bhattacharya opposes centralizing review of CCSG